Topical Insights Into the Post-Approval Controversies of Aducanumab

Código QR

Topical Insights Into the Post-Approval Controversies of Aducanumab

Guardado en:

Detalles Bibliográficos
Autores principales:	Dhiraj Kumar, Dharmendra Kumar Yadav, Md Imtaiyaz Hassan
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	Alzheimer’s drug Aducanumab Neurodegenerative diseases FDA—Food and drug administration Neuropsychological Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/e5a0627f956e42a49988b473d2b2ea66
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Is Aducanumab for LMICs? Promises and Challenges
por: Illangage P. C. Gunawardena, et al.
Publicado: (2021)

Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?
por: Rúben G. R. Pinheiro, et al.
Publicado: (2021)

Protein intake and the use of levodopa in patients with Parkinson's disease
por: de Moraes Fracasso,Bianca, et al.
Publicado: (2013)

Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
por: Sam Gandy, et al.
Publicado: (2021)

Liposome based drug delivery as a potential treatment option for Alzheimer’s disease
por: Carely Hernandez, et al.
Publicado: (2022)

Potential drug–drug interactions in Alzheimer patients with behavioral symptoms
por: Pasqualetti G, et al.
Publicado: (2015)

Sensitivity analysis of FDA´s benchmark nozzle regarding in vitro imperfections - Do we need asymmetric CFD benchmarks?
por: Stiehm Michael, et al.
Publicado: (2020)

Alexidine Dihydrochloride Has Broad-Spectrum Activities against Diverse Fungal Pathogens
por: Zeinab Mamouei, et al.
Publicado: (2018)

Anticholinesterase constituents from the leaves of Spondias mombin L. (Anacardiaceae)
por: Elufioye TO, et al.
Publicado: (2017)

Risk management and regulations for lower limb medical exoskeletons: a review
por: He Y, et al.
Publicado: (2017)

Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives
por: Vyronia Vassilakopoulou, et al.
Publicado: (2021)

Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer’s Disease
por: María Jesús Friedli, et al.
Publicado: (2021)

Drug target insights
Publicado: (2007)

Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases
por: Claudia Riccardi, et al.
Publicado: (2021)

The Challenge of Nanovesicles for Selective Topical Delivery for Acne Treatment: Enhancing Absorption Whilst Avoiding Toxicity
por: Mancuso A, et al.
Publicado: (2020)

Current landscape of clinical development and approval of advanced therapies
por: Carolina Iglesias-Lopez, et al.
Publicado: (2021)

Theoretical insights into the molecular mechanism of I117V mutation in neuraminidase mediated reduction of oseltamivir drug susceptibility in A/H5N1 influenza virus
por: Mohini Yadav, et al.
Publicado: (2021)

Cell Therapy: Types, Regulation, and Clinical Benefits
por: Abed El-Hakim El-Kadiry, et al.
Publicado: (2021)

The Alzheimer’s disease drug development landscape
por: Pieter van Bokhoven, et al.
Publicado: (2021)

Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review
por: Liang JH, et al.
Publicado: (2018)

Producción de tomate y dinámica microbiológica del suelo de invernáculo al aplicar vermicompostas
por: O. Robledo, et al.
Publicado: (2010)

Gut Microbiota Regulation and Their Implication in the Development of Neurodegenerative Disease
por: Peilin Sun, et al.
Publicado: (2021)

Investigación y desarrollo de nuevos medicamentos: de la molécula al fármaco
por: Marovac,Jacqueline
Publicado: (2001)

Daño hepático por fármacos: características clínicas e histológicas en 33 casos
por: Contreras B,Jorge, et al.
Publicado: (2003)

Effects of Carbopol® 934 proportion on nanoemulsion gel for topical and transdermal drug delivery: a skin permeation study
por: Zheng Y, et al.
Publicado: (2016)

The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
por: Hannah Walgrave, et al.
Publicado: (2021)

Entre el consumo de drogas y la drogadicción /
por: Moreno, Rodrigo
Publicado: (2015)

How to develop and implement a national drug policy
Publicado: (2001)

Journal of drug delivery
Publicado: (2011)

Alzheimer’s disease and language impairments: social intervention and medical treatment
por: Klimova B, et al.
Publicado: (2015)

Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs
por: José Manuel Ezquerra-Aznárez, et al.
Publicado: (2021)

Mechanisms and the clinical relevance of complex drug–drug interactions
por: Roberts AG, et al.
Publicado: (2018)

Drugs in R & D.
Publicado: (1999)

Subjective Time in Dementia: A Critical Review
por: Lulu Liu, et al.
Publicado: (2021)

Clinical and pharmacological monitoring of drug safety in pediatrics
por: N. V. Verlan, et al.
Publicado: (2016)

Association between the use of statins and periodontal status: a review
por: Rosenberg,David R, et al.
Publicado: (2019)

Drug discoveries & therapeutics

Síndrome de DRESS con compromiso pulmonar extenso. Una presentación inhabitual
por: Arellano,Javier, et al.
Publicado: (2019)

Reacción por drogas con eosinofilia y síntomas sistémicos (síndrome de DRESS): Estudio retrospectivo de nueve casos
por: Ocampo-Garza,Jorge, et al.
Publicado: (2015)